Arcturus Therapeutics (ARCT) said Monday that its mRNA therapeutic candidate, ARCT-810, showed "significant and consistent" reduction and normalization of abnormally elevated glutamine, according to interim data from a phase 2 trial.
The drug candidate is intended for the treatment of OTC deficiency, a genetic disorder.
The company reported the first significant relative ureagenesis function improvements using a new and optimized 15N-ureagenesis assay.
Meanwhile, multiple administrations of ARCT-810 continued to be safe and well tolerated at all tested dose levels, the company said.
Shares of Arcturus gained more than 2% in recent trading activity Monday.
Price: 13.61, Change: +0.28, Percent Change: +2.10
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。